Zhu Wenjing, Zhao Long, Kong Beihua, Liu Ying, Zou Xin, Han Tongqin, Shi Yongmei
Clinical Research Center, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.
Department of Respiratory and Critical Care Medicine, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.
Ann Transl Med. 2022 Jan;10(2):59. doi: 10.21037/atm-21-6462.
Ovarian cancer (OV) is the leading cause of death in gynecological cancer. The dysregulation of N6-methyladenosine (m6A) modification is commonly found in cancers. However, there is a lack of research into m6A RNA methylation regulators in OV.
The RNA-Seq of 379 OV tissues and 88 healthy ovarian tissues was downloaded from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases, respectively. A Gene Ontology (GO) functional analysis was performed to verify the function of m6A RNA methylation regulators. Kaplan-Meier (K-M) curves and the log-rank (Mantel-Cox) test were used for the survival analysis. A Cox regression analysis was used to identify the genes related to overall survival (OS) and build the prediction model.
m6A RNA methylation regulators were dysregulated in OV tissues compared with normal tissues (P<0.05), and patients with a high expression of and had a poor prognosis (P<0.05). A prognostic model was constructed based on the m6A RNA methylation regulators. Based on the risk signature, the patients were classified into high- and low-risk groups. The low-risk group's OS rate was significantly better than that of the high-risk group. The validity and accuracy of the prognostic model were verified by using TCGA and Gene Expression Omnibus (GEO) datasets, and the risk score from the prognostic model acted as an independent prognostic indicator in predicting the survival of OV patients.
m6A RNA methylation regulators were dysregulated in OV tissues. More importantly, the prognostic model comprising the five selected m6A RNA methylation regulators could be a valuable tool for predicting the prognosis of OV patients.
卵巢癌（OV）是妇科癌症死亡的主要原因。N6-甲基腺苷（m6A）修饰失调在癌症中普遍存在。然而，目前缺乏对卵巢癌中m6A RNA甲基化调节因子的研究。
分别从癌症基因组图谱（TCGA）和基因型-组织表达（GTEx）数据库下载了379份卵巢癌组织和88份健康卵巢组织的RNA测序数据。进行基因本体（GO）功能分析以验证m6A RNA甲基化调节因子的功能。采用Kaplan-Meier（K-M）曲线和对数秩（Mantel-Cox）检验进行生存分析。采用Cox回归分析确定与总生存期（OS）相关的基因并建立预测模型。
与正常组织相比，卵巢癌组织中m6A RNA甲基化调节因子表达失调（P<0.05），且 和 高表达的患者预后较差（P<0.05）。基于m6A RNA甲基化调节因子构建了预后模型。根据风险特征，将患者分为高风险组和低风险组。低风险组的总生存率明显优于高风险组。通过使用TCGA和基因表达综合数据库（GEO）数据集验证了预后模型的有效性和准确性，并且预后模型的风险评分在预测卵巢癌患者生存方面可作为独立的预后指标。
卵巢癌组织中m6A RNA甲基化调节因子失调。更重要的是，包含五个选定的m6A RNA甲基化调节因子的预后模型可能是预测卵巢癌患者预后的有价值工具。
